Abstract
A randomized, double-blind, placebo controlled study to investigate the long-term effect of CyclospasmolR (cyclandelate) on the abnormal permeability of the blood-retinal barrier was performed in 26 patients with insulin-dependent diabetes mellitus for at least 1 year and minimal retinopathy. Cyclospasmol 400 mg or placebo capsules were taken 4 times daily for 12 months by equal numbers in both groups.
Each patient underwent a routine ophthalmoscopic examination, retinal fluorescein angiography and quantitative vitreous fluorophotometry to assess the permeability of the blood-retinal barrier just before the trial and following 6 and 12 months of therapy. Laboratory tests for determining blood and urine glucose levels and blood HbA1-levels were also carried out at these assessments.
Statistically significant changes in diabetic control, in HbA1-levels or in the frequency of retinal microaneurysms could not be shown in either treatment group during the trial, nor were there any significant differences in these parameters between the two groups. Analysis of fluorophotometric data on fluorescein penetration into the left posterior vitreous demonstrated significant reductions in this parameter during the trial compared to the pretreatment level in Cyclospasmol treated diabetics. These changes in the pretreatment level after 6 and 12 months also differed significantly between the two groups.
However, this statistically significant beneficial reduction in fluorescein penetration into the left posterior vitreous did not occur in the right eye in the Cyclospasmol group.
In placebo treated patients a consistently deleterious trend for this parameter was observed for both eyes during the one year study. The consistently beneficial trend in the right eye following Cyclospasmol and the consistently deleterious trend in both eyes following placebo with regard to the abnormal permeability of the blood-retinal barrier of diabetics with minimal retinopathy could probably be explained by the small number of patients in both groups. No side-effects were reported.
Similar content being viewed by others
References
Cunha-Vaz JG, Faria de Abreu JR, Campos AJ, Figo GM: Early breakdown of the blood-retinal barrier in diabetes. Brit J Ophthalmol 59: 649, 1975
Cunha-Vaz JG, Reis Fonseca J, Hagenouw JRB: Treatment of early diabetic retinopathy with cyclandelate. Brit J Ophthalmol 61: 399–404, 1977
Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E: Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 34: 53–59, 1985
Cunha-Vaz JG: Pathophysiology of diabetic retinopathy. Brit J Ophthalmol 62: 351–355, 1978
Van den Hoven WE, Hall DWR, Burns JW: Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate. Brit J Clin Pract 38: Symposium Supplement 34; 31–33, 1984
Kelly ThM, Sanborn GE, Haug PJ, Edwards OG: Effects of insulin infusion pump use on diabetic retinopathy. Arch Ophthalmol 102: 1156–1159, 1984
Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multi-centre trial. New Engl J Med 311: 365–372, 1984
Krupin Th, Waltman SR, Szewczyk P, Koloms B, Farber M, Silverstein B, Becker B: Fluorometric studies on the blood-retinal barrier in experimental animals. Arch Ophthalmol 100: 631–634, 1982
Kupfer C: Aldose reductase and retinopathy, p. 89–91. In: Cogan, D.G., moderator. Aldose reductase and complications of diabetes. Ann Intern Med 101: 82–91, 1984
Lauritzen T, Larsen HW, Frost-Larsen K, Deckert T: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet I: 200–204, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mota, M.C., Leite, E., Ruas, M.A. et al. Effect of cyclospasmol on early diabetic retinopathy. Int Ophthalmol 10, 3–9 (1987). https://doi.org/10.1007/BF00202775
Issue Date:
DOI: https://doi.org/10.1007/BF00202775